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Abstract
Purpose—To compare information from self-report and electronic medical records for four 
common comorbidities (diabetes, hypertension, myocardial infarction, and other heart diseases).
Methods—We pooled data from two multiethnic studies (one case–control and one survivor 
cohort) enrolling 1,936 women diagnosed with breast cancer, who were members of Kaiser 
Permanente Northern California.
Results—Concordance varied by comorbidity; kappa values ranged from 0.50 for other heart 
diseases to 0.87 for diabetes. Sensitivities for comorbidities from self-report versus medical record 
were similar for racial/ethnic minorities and non-Hispanic Whites, and did not vary by age, 
neighborhood socioeconomic status, or education. Women with a longer history of comorbidity or 
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who took medications for the comorbidity were more likely to report the condition. Hazard ratios 
for all-cause mortality were not consistently affected by source of comorbidity information; the 
hazard ratio was lower for diabetes, but higher for the other comorbidities when medical record 
versus self-report was used. Model fit was better when the medical record versus self-reported data 
were used.
Conclusions—Comorbidities are increasingly recognized to influence the survival of patients 
with breast or other cancers. Potential effects of misclassification of comorbidity status should be 
considered in the interpretation of research results.
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Introduction
Evidence has accumulated showing that comorbid conditions influence survival after a 
breast cancer diagnosis [1–12]. Comorbidity data are commonly derived from self-report 
and medical records. Although both sources may be subject to error, medical records are 
generally considered to be a more reliable source of comorbidity information than self-
report [13–18]. Previous studies have explored the accuracy of self-reported comorbidities 
compared to medical records, but they were limited in sample size and racial/ethnic diversity 
[13–22]. Attention to non-differential misclassification of comorbidity status by race/
ethnicity, however, is necessary to avoid the substantial bias that can occur when 
misclassification of covariates differs, not by disease status, but instead by exposure 
classification [23]. Furthermore, the accuracy of self-reports has been assessed in general 
population and disease-specific cohorts, but no study has specifically examined the accuracy 
of comorbidities reported by breast cancer patients.
For 1,936 women with breast cancer who were members of the Kaiser Permanente Northern 
California (KPNC) health plan at the time of their breast cancer diagnoses and are a part of 
the California Breast Cancer Survivorship Consortium (CBCSC), we compared the 
comorbidity status obtained by self-report (in-person interviews or self-administered 
questionnaires) to that found in electronic medical records (EMR) for four common 
comorbidities available in our studies. The specific comorbidities we examined were 
diabetes, hypertension, myocardial infarction (MI), and other heart diseases, representing a 
selected subset of the comorbidities that are of interest in breast cancer survival. We 
explored whether discrepancies between the two sources of comorbidity information 
differed by demographic characteristics such as age, race/ethnicity, and neighborhood 
socioeconomic status (SES), and by comorbidity characteristics such as timing and 
treatment for comorbidity. We also examined the impact of source of comorbidity 
information on hazard ratios (HR) for all-cause mortality in multivariable models.
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Methods
Study population and comorbidity data collection
This analysis included a subset of women diagnosed with breast cancer who are part of the 
CBCSC, which harmonized and pooled existing questionnaire data from six studies of breast 
cancer to explore racial/ethnic disparities in breast cancer survival [12, 24–26]. Two of these 
studies, the San Francisco Bay Area Breast Cancer Study (SFBCS) [27] and the Life After 
Cancer Epidemiology (LACE) study [28], enrolled participants who were members of 
Kaiser Permanente Northern California (KPNC) and had obtained self-reported information 
on select comorbidities. Individual studies received Institutional Review Board (IRB) 
approval from their respective institution(s) to participate in this collaboration, and IRB 
approval permitting the use of California Cancer Registry (CCR) data was also obtained 
from the State of California Committee for the Protection of Human Subjects.
The SFBCS is a population-based case–control study of breast cancer in which participants, 
who were enrolled during the years 1999–2003, were interviewed using a structured 
questionnaire. A subset of study participants (those enrolled later in the recruitment period) 
was asked whether a doctor had ever diagnosed specific comorbidities (diabetes, 
hypertension, heart disease) before the breast cancer diagnosis, and whether they were 
currently taking any medication for the condition. Women who were KPNC members were 
included in this analysis.
LACE participants were KPNC members and breast cancer survivors enrolled in the cohort 
study during the years 2000–2002 within 39 months (mean of 22 months) after breast cancer 
diagnosis. The LACE baseline questionnaire assessed history (as of the date of interview) of 
the four conditions of interest (diabetes, hypertension, MI, other heart diseases), as well as 
use of insulin injections, oral hypoglycemic medications, diuretics, blood pressure 
medications, and other medications for heart problems. Participants were asked two 
questions about being treated for diabetes: Did they have diabetes requiring insulin (yes/no), 
and did they have diabetes not requiring insulin (yes/no). Women were coded as having 
diabetes if they replied “yes” to either question. The presence of other heart diseases was 
determined by a positive response to “Other heart-related problems (not specified above).”
Kaiser Permanente Medical Records (KPMR)
Through linkage with the CCR, we identified 896 SFBCS and 1,731 LACE participants who 
were diagnosed with breast cancer at a KPNC hospital. We then limited breast cancer 
diagnoses to those recorded from 1997 and onward, given that KPNC electronic data capture 
began consistently in 1996, thus allowing for capture of at least 1 year of comorbidity data 
before breast cancer diagnosis. As a result, 1,936 participants in SFBCS (n = 327) and 
LACE (n = 1,609) were included in this analysis.
The KPMR is supported by the Virtual Data Warehouse (VDW) of the former Health 
Maintenance Organization Research Network (now called the Health Care Systems 
Research Network) which uses input from EMR and insurance data to create research-
quality databases [29]. For the eligible cohort, we searched the KPMR for first diagnosis of 
the four comorbidities of interest from at least one year prior to the patient’s date of breast 
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cancer diagnosis, using the following ICD-9 codes: diabetes: 249.0–249.91, 250.0–250.93; 
hypertension: 401.0–405; MI: 410; and other heart diseases: 411–414, 415–417, 420–429, 
390–392, 393–398, 746.9. These codes enumerated for other heart diseases include 
atherosclerosis, heart failure, and congenital anomalies, among others. Along with the 
diagnostic code, we obtained the date associated with the first diagnosis of the comorbidity 
in the KPMR. We also extracted medications (prescriptions filled) for diabetes (insulin, 
sulfonylureas, and others) and hypertension (diuretics, angiotensin-converting enzyme 
inhibitors, calcium channel blockers, and others) from the KPNC VDW outpatient pharmacy 
database.
California Cancer Registry (CCR) data
Data on patient demographic and tumor characteristics were available from the CCR, 
including age at diagnosis, American Joint Committee on Cancer (AJCC) stage, tumor size, 
grade, estrogen receptor (ER) and progesterone receptor (PR) status, number of positive 
nodes, prior cancer diagnoses, treatment (surgery, chemotherapy, radiation), neighborhood 
SES, and marital status. Study participants were linked to the CCR to obtain vital status as 
of 31 December 2010 and, among those who died, date of death.
Statistical analysis
Concordance—We defined the concordance (reference) date as the date for which the 
comorbidity status was asked in the study questionnaire (the year of breast cancer diagnosis 
for SFBCS and date of interview for LACE). Comorbidity status in the KPMR was positive 
if the comorbidity ICD-9 code was found in the patient’s EMR on or prior to the 
concordance date. Sensitivity, specificity, and kappa statistics were calculated using these 
criteria. P values for differences in sensitivity and specificity between groups defined by 
dichotomized demographic variables [e.g., race/ethnicity (non-Hispanic White vs. all other), 
age (<60 vs. ≥60 years)] were calculated using Fisher’s exact tests that compared the 
frequencies of correct/incorrect reporting between the two groups within participants with 
the condition (for sensitivity) or without the condition (for specificity). The KPMR was 
treated as the “gold standard” in sensitivity and specificity calculations. Although EMRs 
may also contain errors, we refer to a woman with a comorbidity diagnosis in her KPMR in 
the appropriate time frame as having the comorbidity, while we refer to a woman answering 
positively to the comorbidity in the study questionnaire as reporting the comorbidity. Kappa 
is a measure of inter-observer agreement with a value of 0 indicating no better than chance 
and a value of 1.0 indicating perfect agreement [30]. Kappa values in excess of 0.80 are 
commonly considered to be excellent.
We stratified measures of concordance by race/ethnicity (non-Hispanic Whites vs. all 
others), age at interview (<60 vs. ≥60 years), neighborhood SES [block-group-level 
composite index based on statewide quintiles [31] collapsed into low (quintiles 1–3) or high 
(quintiles 4, 5)], and education (less than college graduate vs. college graduate).
Reasons for discordance—We explored reasons for false negatives (i.e., women having 
a comorbidity according to KPMR but not reporting it) by considering the lag time between 
self-report and KPMR comorbidity diagnosis and medication use according to the KPMR. 
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We first evaluated whether some of the discordance could be explained by women with a 
recent diagnosis of comorbidity not yet being sure about disease status. Although medication 
usage was not considered when determining comorbidity status either according to the 
KPMR or according to self-report, we explored whether some women who were not treated 
with medications might have reported that they did not have the comorbidity, or conversely, 
that women whose disease was controlled by medication might have responded that they did 
not have the comorbidity.
Associations of comorbidities with all-cause mortality by source of 
comorbidity information—We evaluated the effect of source of comorbidity information 
on associations of comorbidities with all-cause mortality. Specifically, for each comorbidity, 
we compared hazard ratio (HR) estimates based on self-report versus EMR. We used Cox 
proportional hazards regression models to estimate HRs and 95 % confidence intervals 
(CIs), stratifying by study (LACE or SFBCS) and adjusting for age at breast cancer 
diagnosis [age and ln(age)], AJCC stage (I, II, III, IV, or unknown), tumor size (<1, 1 to<5, 
or ≥5 cm), grade (I, II, III/IV, or unknown), ER/PR status (ER+/PR+, ER+/PR−, ER−/PR+, 
ER−/PR−, unknown), number of positive nodes (0, ≥1, or unknown), prior cancer (yes or 
no), chemotherapy (yes, no, or unknown), breast surgery (none, mastectomy, lumpectomy, or 
other), age at first birth (nulliparous,<20, 20–24, 25–29, 30–34, or ≥35), alcohol 
consumption (none, ≤2 drinks/week, >2 drinks/week, or unknown), smoking (never, past <1 
pack/day, past >1 pack/day, current ≤1 pack/day, current >1 pack/day, or unknown), 
education (<high school, high school, some college, college graduate, or unknown), marital 
status (single, married, separated/divorced, widowed, or unknown), neighborhood SES 
(statewide quintile or unknown), race/ethnicity (non-Latina White, African American, 
Latina, Asian American, or other), nativity (USA, other, or unknown), and body mass index 
(BMI) (<18.5, 18.5–24.9, 25.0–29.9, 30.0–34.9, 35.0–39.9, ≥40 kg/m2, or unknown). For 
each comorbidity, we used the attained age model for all-cause mortality to evaluate the 
effect of the comorbidity data source on the HR estimates for the comorbidity and for the 
other covariates contained in each of the models. Model fit was assessed using the Akaike 
information criterion (AIC), which adjusts for the number of terms in the model and the 
number of observations used.
All data were analyzed using SAS for Windows, version 9.4 (SAS Institute, Cary, N.C.). All 
p values are two-sided.
Results
The mean age at interview of women in this validation study was 60.4 (standard deviation, 
SD 11.0) years (Table 1). Most women (71 %) were non-Hispanic White, and 33 % were 
college graduates. Between 1,609 and 1,936 women with breast cancer were included in the 
analyses of each of the four comorbidities we studied.
Specificity was high for diabetes, hypertension, MI, and other heart diseases, ranging from 
96.0 % to 99.5 % (Table 2). Sensitivity ranged from 48.0 % (other heart diseases) to 90.5 % 
(MI). Specificity was similar in non-Hispanic Whites and other race/ethnicities, but 
sensitivity for hypertension was higher in racial/ethnic minorities than in non-Hispanic 
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Whites (unadjusted p = 0.0004, adjusted for study p = 0.02). Kappa statistics ranged from 
0.50 for other heart diseases to 0.87 for diabetes. Data within the other race/ethnicity 
category were stratified into African American, Hispanic, Asian American, and others, and 
results are also shown in Table 2. The small cell sizes, however, provide limited 
interpretation.
When analyses were stratified by age at diagnosis or interview (Table 3), we found that for 
each comorbidity, sensitivity was similar in women <60 years and those ≥60 years of age; 
however, specificity for MI was higher in younger women compared to older women (1.00 
and 0.98, respectively, p = 0.0003). We considered additional cut points for age (65, 70, and 
75 years), and results were similar (data not shown). For each comorbidity, sensitivity and 
specificity did not differ by neighborhood SES or education, except that specificity for MI 
was higher in the high (quintile 4 or 5) versus low SES group (0.99 and 0.98, respectively, p 
= 0.01) and in college graduates versus those with lower education (0.99 and 0.98, 
respectively, p = 0.01).
We explored possible explanations for the false positives (i.e., “yes” according to 
questionnaire response but “no” according to KPMR; Table 2). For diabetes, there were 
eight false positives; three of these women reported diabetes not requiring insulin and one 
woman was taking diabetes medication per her KPMR, although no diabetes diagnosis was 
present. Of the 14 women who were false positives for hypertension, one reported taking 
diuretic and antihypertensive medication, yet neither of these medications was found in her 
KPMR. Another woman was taking antihypertensive medication per her KPMR. There were 
17 women who were false positives for MI. Sixteen of these women were positive for 
ischemic heart disease in their KPMR. Five women, including four who had ischemic heart 
disease, reported a date for the MI which was prior to their date of enrollment in KPNC. 
There were 58 false positives for other heart diseases. Among these women, four had 
diabetes, 29 had hypertension, and one had a MI in her KPMR, potentially accounting for 29 
(50 %) of these false positives. No explanation for the other discrepancies could be found.
We also evaluated reasons for false negatives, i.e., women who were positive for a 
comorbidity per their KPMR, but responded negatively according to questionnaire data 
(Table 4). Women who were taking medications for diabetes or hypertension according to 
their KPMR were significantly more likely to report the comorbidity than women who were 
positive for the disease but not taking medication (p ≤ 0.0001 for both diabetes and 
hypertension, Table 4). Women who had been diagnosed with diabetes or hypertension more 
than 1 year prior to their interview date were more likely than women who had been 
diagnosed more recently to report that comorbidity on the study questionnaire (85 % vs. 
68 % for diabetes, p = 0.03; 82 % vs. 58 % for hypertension, p = 0.0002). Only two women 
did not report a MI that was shown in their KPMR.
In Table 5, we show for each comorbidity the HRs for all-cause mortality derived from 
models where all specifications are the same except the source of information on 
comorbidity (self-report vs. KPMR). The HR estimates for the comorbidities were not 
consistently affected by source of comorbidity information. For diabetes, the HR estimates 
based on self-report were higher than those based on the KPMR, but for the other 
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comorbidities, HRs based on self-report were lower. Regardless of how diabetes status was 
determined, diabetes was a significant risk factor for all-cause mortality among women with 
breast cancer; the risk was higher when self-reported questionnaire data (vs. KPMR data) 
were used, but the 95 % CIs were overlapping. Hypertension and other heart diseases were 
associated with statistically significantly increased HRs when the KPMR data were used 
(HR = 1.55 for hypertension, HR = 1.51 for other heart diseases), but these associations 
were not statistically significant when self-reported data were used (HR = 1.22 for 
hypertension; HR = 1.07 for other heart diseases). HRs for MI were nonsignificantly 
elevated regardless of data source.
We compared the HR estimates and p values obtained using self-report versus KPMR for all 
covariates in each of the comorbidity models. The source of comorbidity data did not 
substantially affect the HR estimate for any of the covariates in any of the comorbidity 
models. For each categorical covariate (we did not include the two continuous covariates 
[age and ln(age)] because their HRs are dependent on units of measurement), we calculated 
the absolute value of the difference between the HR in the model using the self-reported 
comorbidity data and the HR using the KPMR data. The mean (SD) difference was 0.04 
(0.06).
Model fit was similar for diabetes and MI regardless of data source, but was better for 
hypertension and other heart diseases when KPMR data were used (see AIC, Table 5).
Discussion
In this analysis, we investigated a selected number of major comorbidities that are of interest 
in breast cancer survival. We compared self-reported to EMR ascertained comorbidity status 
in a multiethnic population of breast cancer patients, and found that sensitivity and 
specificity varied by comorbidity and had generally excellent specificity, but weaker 
sensitivity. When statistically significant differences in sensitivity or specificity were found 
between subgroups defined by race/ethnicity, age, neighborhood SES, or education, the 
group more likely to have the comorbidity was more likely to report the condition, 
suggesting that there may be some amount of confusion regarding borderline cases. For 
example, women who know that they are at high risk for a condition may be more likely to 
interpret borderline results as definitive diagnoses. We also found that model fit for survival 
was somewhat superior when the EMR rather than self-report was used to determine 
comorbidity, but that risk estimates were similar regardless of data source.
Data discrepancies between self-report and the EMR may have occurred for several reasons, 
including misunderstanding of the questions such as the relevant date of interest. 
Additionally, women taking medication may have not reported the condition due to disease 
management by medication, or women not requiring medication may have not reported 
having a condition because it was a borderline disease. There were 34 false negatives for 
diabetes, and 62 % of these women were not taking diabetes medications according to their 
KPMR, indicating that they may have had relatively mild disease. There were 156 false 
negatives for hypertension; yet, according to the KPMR, 63 % were taking medication 
commonly prescribed for hypertension. This could indicate either a limitation in the EMR or 
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that women were taking these medications for reasons other than hypertension. Sensitivity 
was less than 50 % for other heart diseases, most likely due to the less specific question and 
ambiguity regarding what should be included in this category. Although the ICD-9 codes 
selected to indicate other heart diseases are unambiguous, women may not have reported 
some conditions, particularly those that were mild. Our data were not detailed enough to 
determine concordance by specific heart disease (such as atherosclerosis or heart failure), 
nor to determine whether a condition was serious or mild.
Errors may also exist within medical record data, and some may argue that the EMR should 
not be considered the gold standard. In this study, we found similar or improved model fit 
for the KPMR data compared to self-report. Thus, even though we have no way of 
determining which data source was more correct, we found that comorbidity data from the 
KPMR better predicted survival after diagnosis of breast cancer. The accuracy and 
completeness of EMRs in general are likely to increase in the future; however, increased 
accuracy does not necessarily equate to increased prognostic value. For example, a 
participant may choose to not report a comorbidity that was diagnosed long ago and has 
since resolved with lifestyle modifications. While the comorbidity may be found in a 
sufficiently complete EMR, it may be unrelated to survival. Thus, attention to the extraction 
of relevant EMR data will be necessary to obtain the best models possible.
Our results are generally consistent with those from previous studies that have investigated 
comorbidity concordance between participant responses and medical records (Table 6) [13–
22]. Our finding of high concordance for diabetes (kappa = 0.87) agrees with findings from 
10 previous studies (mean kappa unweighted by sample size = 0.85, range 0.75–0.97). Our 
data also show high concordance for hypertension (kappa = 0.81), which is compatible with 
most previous studies. Our concordance for MI is in the middle of a wide range of kappas 
found in six previous studies, and, similar to three previous studies, we found modest kappas 
for other heart diseases. There is less consistent information on whether concordance differs 
by age, education, or race/ethnicity. Within our limited data by specific race/ethnicity 
groups, we found little evidence for concordance differences by race/ethnicity. The largest 
previous study [16] found generally similar concordance by age and education, whereas 
other studies found situations where concordance was worse for those of older age or lower 
education [14, 15, 18–20].
The real measure of whether data from different sources are sufficiently concordant, 
however, depends on the effect any misclassifications would have on risk estimates. Diabetes 
was a statistically significant risk factor for overall mortality regardless of the source of 
comorbidity data, but the HR was greater when self-reported data were used. In contrast, 
hypertension was significantly associated with overall mortality when KPMR data were 
used, whereas a smaller nonsignificant increase in risk was found when self-reported data 
were used. Higher HR estimates were found for hypertension, MI, and other heart diseases 
when KPMR data were used. Attenuation of HR estimates due to non-differential 
misclassification of data is an expected result; however, it may also be true that women with 
false-negative comorbidity status have mortality risks exceeding those of true positives.
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Despite the potential for comorbidities to confound the relationships between many of our 
model covariates and survival, source of comorbidity data had little effect on the HR 
estimates for the covariates in our models for all-cause mortality. These findings are not 
surprising given that comorbidity was not a strong confounder in these models regardless of 
data source. In future studies where comorbidity is expected to be an important confounding 
variable, and clearly when the comorbidity itself is the variable of interest, special attention 
is warranted to ensure that the best possible data are obtained.
The increasing availability of EMR systems which can be used to address specific research 
questions in a timely and comprehensive manner may allow us to rely less on questionnaire-
based data in the future. Nevertheless, many studies still require specific or diverse 
populations which cannot be found under the umbrella of one medical record system. 
Evaluation of results from studies which rely on self-reports versus those based on medical 
record data will continue to be informative. The results from this study suggest that 
differences in accuracy of self-reported comorbidities by various demographic groups are 
not likely to hinder comparisons of the association between comorbidity and survival.
Although these analyses concern the use of data for research purposes, the potential for 
errors affecting medical treatment needs to be considered. The presence of a comorbidity 
may affect the course of treatment for the comorbidity or for breast cancer [12]; thus, these 
findings may indicate a need for better coordination of care between multiple providers and 
better communication with the patient.
This study’s strengths include its large sample size, the ability to explore concordance of 
self-reported comorbidities compared to the EMR, and the low percentage (<3 %) of missing 
comorbidity data among women asked about these conditions. We have documented 
concordance rates for four common comorbidities and explored causes for discrepancies, 
including race/ethnicity, age, neighborhood SES, education, time since comorbidity 
diagnosis, and use of medication for the condition. In addition, to our knowledge, this is the 
first study to explore the effect of comorbidity data source on model fit or parameter 
estimates.
Although our sample size was large, some variation in concordance by demographic and 
other characteristics may have been missed due to small subgroup sample size. Another 
limitation of this and similar studies is that concordance rates are undoubtedly affected by 
the precise wording and the manner in which the comorbidity questions are asked. Thus, our 
results may not be generalizable to studies which have used different wording in their 
questionnaires. We were unable to determine the extent to which borderline cases comprised 
the discordances. Nevertheless, we have been able to highlight some issues that will apply 
when other researchers develop questionnaires and evaluate results obtained with them.
In conclusion, an EMR, when available and accessible, is likely to be the best source for 
comorbidity data when used as either a primary risk factor or as a covariate in a study of 
breast cancer survival. Self-reported data can provide good results, especially when the 
comorbidity data are used as covariates in multivariable models. Potential effects of 
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misclassification of comorbidity status should be considered when research results are 
interpreted, but large differences in concordance by demographic groups seem unlikely.
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Table 1
Demographic characteristics of CBCSC Comorbidity Validation Study, 1997–2010
Total (n = 1,936) LACE (n = 1609) SFBCS (n = 327)
Age at interview 60.4 (11.0) 61.0 (10.9) 57.6 (11.0)
Education
 Less than high school 171 (8.8) 83 (5.2) 88 (26.9)
 High school graduate 446 (23.0) 360 (22.4) 86 (26.3)
 Some college 679 (35.1) 585 (36.4) 94 (28.8)
 College graduate 633 (32.7) 574 (35.7) 59 (18.0)
 Unknown 7 (0.4) 7 (0.4) 0 (0)
Race/ethnicity
 Non-Hispanic White 1,370 (70.8) 1,327 (82.5) 43 (13.1)
 African American 133 (6.9) 72 (4.5) 61 (18.7)
 Hispanic 292 (15.1) 69 (4.3) 223 (68.2)
 Asian American 103 (5.3) 103 (6.4) 0 (0)
 Other 38 (2.0) 38 (2.4) 0 (0)
Number of breast cancer patients asked comorbidity question
 Diabetes 1,936 1,609 327
 Hypertension 1,936 1,609 327
 Myocardial infarction 1,609 1,609 0
 Other heart disease 1,768 1,609 159
CBCSC California Breast Cancer Survivorship Consortium, LACE Life After Cancer Epidemiology, SFBCS San Francisco Bay Area Breast 
Cancer Study
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Table 3
Sensitivity and specificity by age, neighborhood SES, study, and education in CBCSC Comorbidity Validation 
Study, 1997–2010
Diabetes Hypertension Myocardial infarction Other heart disease
Age at interview <60 years
 n with comorbidity 57 223 3 60
 Sensitivity 0.86 0.78 1.00 0.42
 n without comorbidity 871 709 729 757
 Specificity 1.00 0.99 1.00 0.93
Age at interview ≥60 years
 n with comorbidity 141 560 18 213
 Sensitivity 0.82 0.81 0.89 0.50
 n without comorbidity 820 413 806 689
 Specificity 1.00 0.99 0.98 0.96
P values for difference by age group
 Sensitivity 0.54 0.37 1.00 0.31
 Specificity 1.00 0.59 0.0003 0.79
SES ≤3 Quintile
 n with comorbidity 88 271 9 97
 Sensitivity 0.85 0.80 0.89 0.55
 n without comorbidity 533 354 463 441
 Specificity 0.99 0.99 0.98 0.97
SES > 3 Quintile
 n with comorbidity 105 488 12 166
 Sensitivity 0.81 0.80 0.92 0.43
 n without comorbidity 1,096 723 1,010 950
 Specificity 1.00 0.99 0.99 0.96
P values for difference by SES
 Sensitivity 0.45 0.85 1.00 0.10
 Specificity 0.45 0.77 0.01 0.47
<College graduate
 n with comorbidity 97 279 7 94
 Sensitivity 0.87 0.80 1.00 0.52
 n without comorbidity 504 326 416 397
 Specificity 1.00 0.98 0.98 0.97
≥College graduate
 n with comorbidity 99 500 13 179
 Sensitivity 0.79 0.80 0.85 0.46
 n without comorbidity 1,184 795 1,115 1,046
 Specificity 0.99 0.99 0.99 0.96
P values for difference by education
 Sensitivity 0.19 1.00 0.52 0.37
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Diabetes Hypertension Myocardial infarction Other heart disease
 Specificity 0.45 0.25 0.01 0.45
CBCSC California Breast Cancer Survivorship Consortium, MI myocardial infarction, SES socioeconomic status
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Table 5
Hazard ratios (95 % CI) for race/ethnicity and comorbidities by source of comorbidity data in the CBCSC 
Comorbidity Validation Study, 1997–2010
Study Questionnaire KPMR
HRa 95 % CI HR 95 % CI
n deaths + censored 1,936 1,936
Diabetes model (n = 1,936)
 No 1.00 1.00
 Yes 1.65 1.20, 2.25 1.44 1.07, 1.95
 Missing 0.70 0.34, 1.45
 Akaike information criterionb 3,938 3,940
Hypertension model (n = 1,936)
 No 1.00 1.00
 Yes 1.22 0.96, 1.54 1.55 1.22, 1.96
 Missing 0.93 0.37, 2.31
 Akaike information criterion 3,945 3,933
Myocardial infarction model (n = 1,609)
 No 1.00 1.00
 Yes 1.40 0.79, 2.49 1.73 0.82, 3.66
 Missing 0.44 0.20, 0.96
 Akaike information criterion 3,485 3,488
Other heart diseases model (n = 1,768)
 No 1.00 1.00
 Yes 1.07 0.77, 1.49 1.51 1.17, 1.96
 Missing 0.82 0.43, 1.55
 Akaike information criterion 3,736 3,725
CBCSC California Breast Cancer Survivorship Consortium, CI confidence interval, HR hazard ratio, KPMR Kaiser Permanente medical record
aCox proportion hazards regression model for all-cause mortality using attained age as the time metric, stratification by study, and adjustment for 
age, ln(age), AJCC stage, differentiation, ER/PR, nodes, tumor size, prior tumor, chemotherapy, surgery, age at first birth, alcohol, education, 
marital status, neighborhood socioeconomic status, race/ethnicity, smoking, nativity, and BMI
b
Lower values of Akaike information criterion indicate better model fit
Cancer Causes Control. Author manuscript; available in PMC 2018 January 31.
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